# VA STARPORT (NCT04787744)

> Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04787744
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: VA Office of Research and Development
- Conditions: Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer
- Interventions: PET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin; ADT + Nilutamide, Flutamide, & Bicalutamide; Degarelix & Relugolix; ADT + Docetaxel +/- prednisone; ADT + Abiraterone + Prednisone; ADT + Abiraterone + Methylprednisolone; ADT + Apalutamide; ADT + Enzalutamide; Prostate-directed Radiation for De novo oligometastatic prostate cancer
- Enrollment: 378
- Primary outcome: Castration-resistant prostate cancer-free survival (CRPC-free survival)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 10

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=va-starport-nct04787744

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04787744", "email": "<work email>"}; the inbox owner confirms by the emailed link.